Browse the corpus

Eptifibatide is a glycoprotein IIb/IIIa class platelet inhibitor drug that reduces ischemic cardiac events in specific patient populations. The FDA has approved this medication for the medical management of unstable angina and non-ST elevation myocardial infarction (NSTEMI). The FDA also approved eptifibatide for patients undergoing percutaneous intervention (PCI), including intracoronary stenting. The IMPACT-II trial proved that eptifibatide use with heparin and aspirin reduces ischemic events following a PCI, especially in individuals with unstable angina. This activity outlines the indications, mechanism of action, administration, adverse effects, contraindications, warnings, precautions, monitoring, and toxicity of eptifibatide. Participating clinicians understand eptifibatide's role in emergency and chronic medical care, highlighting significant risks of bleeding and thrombocytopenia, which require vigilant monitoring by the interprofessional healthcare team. Effective communication and collaboration among team members, including specialists and ordering clinicians, are essential for optimizing therapeutic outcomes with eptifibatide and differentiating potential complications like heparin-induced thrombocytopenia (HIT). Objectives: Identify appropriate indications for eptifibatide therapy in acute coronary syndrome (ACS) management. Assess patient response to eptifibatide therapy through appropriate monitoring parameters. Differentiate between the mechanisms of action of eptifibatide and other antiplatelet agents commonly used in acute coronary syndrome. Collaborate among interprofessional team members to improve treatment efficacy and outcomes for patients under eptifibatide therapy. Access free multiple choice questions on this topic.

Limited knowledge of the overdosage of eptifibatide in literature is evident. In preclinical studies, eptifibatide was not lethal to experimental animals in a dosage of 2 to 5 times the recommended MRHD (maximum daily human dose). However, symptoms of acute toxicity were evident, such as loss of righting reflex, dyspnea, ptosis, decreased muscle tone in rabbits, and petechial hemorrhages in monkeys' femoral and abdominal areas. From in vitro studies, eptifibatide has limited protein binding; consequently, it may be removed from the plasma by dialysis (according to the manufacturer's labeling). Bleeding at IV sites is the most common adverse effect. Simultaneous use of NSAIDs or other antiplatelet drugs and renal insufficiency would increase the risk of bleeding. No specific antidote for eptifibatide toxicity exists. Clinicians should discontinue eptifibatide when platelet counts are under 50000 cells/µL. A platelet transfusion should be ordered when platelet counts are less than 20000 cells/µL or if significant bleeding occurs.[17] According to the American Association of Poison Control Center (National Poison Data System), rare case fatalities have been reported due to eptifibatide. Administer with caution due to the hazard of therapeutic error.[24][25]

Eptifibatide is useful in treating ACS and following PCI. The interprofessional healthcare team, including cardiologists and other specialists, mid-level practitioners, nurses, and pharmacists, should know that bleeding and thrombocytopenia are significant complications following the administration of eptifibatide. They should coordinate to identify these complications. Nurses should be first in line to monitor for adverse events, especially bleeding. Pharmacists should conduct thorough medication reconciliation and verify dosing since medication errors in either area can lead to therapeutic failure or severe bleeding. Any concerns in these areas require immediate communication with the team involved in care. A hematology consult should be obtained for severe thrombocytopenia. Eptibitaide is a high-risk medication, according to the Institute for Safe Medication Practices. Also, since heparin is used in conjunction with eptifibatide in ACS treatment and during PCI, it is imperative to learn how to differentiate heparin-induced thrombocytopenia (HIT) from eptifibatide-induced thrombocytopenia. Consequently, interprofessional communication and coordination between ordering clinicians (MD, DO, NP, PA), specialists, pharmacists, and nurses can help patients achieve optimal therapeutic outcomes with eptifibatide.